S
Surrozen, Inc. (SRZN)
NCM – Real Time Price. Currency in USD
28.90
+0.90 (3.21%)
At close: Mar 27, 2026, 4:00 PM EDT
28.88
-0.02 (-0.07%)
After-hours: Mar 27, 2026, 6:50 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
28.90
+0.90 (3.21%)
At close: Mar 27, 2026, 4:00 PM EDT
28.88
-0.02 (-0.07%)
After-hours: Mar 27, 2026, 6:50 PM EDT
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-β, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Craig C. Parker M.B.A. | CEO, President & Director |
| Date | Type | Document |
|---|---|---|
| 2026-01-30 | 8-K | srzn-20260126.htm |
| 2025-11-07 | 10-Q | srzn-20250930.htm |
| 2025-10-17 | 8-K | srzn-20251014.htm |
| 2025-08-08 | S-8 | srzn-20250808.htm |
| 2025-05-21 | CORRESP | filename1.htm |
| 2025-05-20 | S-3 | srzn_s-3_shelf_202505.htm |
| 2025-05-15 | 8-K | srzn-20250514.htm |
| 2025-05-09 | 8-K | srzn-20250509.htm |
| 2025-04-29 | CORRESP | filename1.htm |
| 2025-04-23 | S-3 | srzn_s-3_20250423.htm |